TDACW vs CRL

Analysts rate Charles River Laboratories International, Inc.

(CRL) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Charles River Laboratories International, Inc.

(CRL) delivered a total return of -46. 9%, compared to -95. 8% for Translational Development Acquisition Corp. (TDACW). Over 10 years, the gap is even starker: CRL returned +119. 2% versus TDACW's -70. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Translational Development Acquisition Corp.

(TDACW) is the lower-risk stock at -0. 76β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately -301% more volatile than TDACW relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Charles River Laboratories International, Inc.

grew EPS -1555. 0% year-over-year, compared to -54. 2% for Translational Development Acquisition Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Translational Development Acquisition Corp.

(TDACW) is the more profitable company, earning 0. 0% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus 0. 0% for TDACW. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Translational Development Acquisition Corp.

(TDACW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 76)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TDACW: -70. 6%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TDACW (Financial Services) and CRL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.